Effect of esketamine as an adjunct to multimodal analgesia in patients undergoing open gynecologic oncology surgery: a double-blind, randomized clinical trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062726

Enrollment

Unknown

Registered

2022-08-16

Start date

2022-08-16

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

open gynecologic oncology surgery

Interventions

Study group:intraoperative intravenous infusion of low dose esketamine

Control group:intravenous infusion of equal dose of saline

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Eligible subjects were patients aged between 18 and 65 years. 2. American Society of Anesthesiologists (ASA) physical status I-III. 3. Female patients undergoing elective open gynecological oncology surgery were screened for inclusion in the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria were: 1. significant cardiovascular, gastric ulcer, hepatic, or renal disease; 2. preoperative treatment with opioids or corticosteroids; allergies or contraindications to any drug used in the study; 3. pregnancy or breastfeeding, or refusal to participate in the study.

Design outcomes

Primary

Measure	Time frame
quality of recovery;	—

Secondary

Measure	Time frame
pain score;morphine use;	—

Countries

China

Contacts

Public ContactZhiYu Geng

Department of Anesthesiology, Peking University First Hospital

gengzhiyu2013@163.com+86 13681121461

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026